November 1, 2022
Ono President Gyo Sagara Ono Pharmaceutical enjoyed its revenue soaring 24.5% year on year in the first half of FY2022, driven by the brisk performance of the PD-1 inhibitor Opdivo (nivolumab) and the SGLT2 inhibitor Forxiga (dapagliflozin). In April-September, the...read more